HEALTH Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome Wednesday, March 11, 2026 · quoin pharmaceuticals, inc. Advertisement Read Original Article → Related Dispatches [US] · Jun 15 Factbox-What the US and Iran Say They Have Agreed in the Memorandum to End the War [US] · Jun 15 Israel Expects New Air Defence Orders From Europe Due to Russia Concerns [US] · Jun 15 UN Human Rights Chief Welcomes US-Iran Deal, Urges Restraint in the Region